Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
977 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (401)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03469557 | BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma | completed | Phase 2 | 30 | BeiGeneINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04144517 | A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer | completed | Phase 2 | 14 | Mural Oncology, IncINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05286619 | A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)(PIPER) | recruiting | Phase 2 | 63 | University of MalayaOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT03714828 | Study of TVEC in Patients With Cutaneous Squamous Cell Cancer | completed | Phase 2 | 11 | University of ArizonaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer(OPTIMA) | completed | Phase 2 | 62 | University of ChicagoOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06137378 | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44](ELOS) | recruiting | Phase 2 | 140 | University of LeipzigOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT03521570 | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer | completed | Phase 2 | 62 | Emory UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05724329 | Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | active not recruiting | Phase 2 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06510660 | Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC(RICE) | recruiting | Phase 2 | 48 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588335 | BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Henan Provincial People's HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06599775 | Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer | not yet recruiting | Phase 2 | 42 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | withdrawn | Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT06577311 | Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | unknown | Phase 2 | 20 | The Center for Clinical and Cosmetic ResearchOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06572514 | De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC | recruiting | Phase 1 / Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03284424 | Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) | completed | Phase 2 | 159 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Aug 23, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT06007729 | ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 170 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05182866 | ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | unknown | Phase 2 | 9 | Rakuten Medical, Inc.INDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06100497 | Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | terminated | Phase 1 / Phase 2 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02777385 | Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | completed | Phase 2 | 80 | Dan ZandbergOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jul 26, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 138 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06508229 | Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 | 65 | Harbin Medical UniversityOTHER | 0 | Jul 18, 2024 | clinicaltrials |
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02383927 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | completed | Phase 2 | 63 | Kura Oncology, Inc.INDUSTRY | 10 | Jul 11, 2024 | clinicaltrials |
| NCT04839471 | BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)(BEAR) | completed | Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06487702 | A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 70 | Rui-hua Xu, MD, PhDOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04435197 | Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma(PALACE-2) | completed | Phase 2 | 143 | Ruijin HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT01581840 | Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus | completed | Phase 1 / Phase 2 | 45 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02964559 | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | completed | Phase 2 | 11 | Emory UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03719690 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy(AIM-HN/SEQ-HN) | completed | Phase 2 | 296 | Kura Oncology, Inc.INDUSTRY | 16 | Jun 21, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 23, 2024source: clinicaltrials